The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia

P. Maslak, Stephen D Nimer

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Suppression of normal hematopoiesis is a frequent complication of cancer or its treatment. The basis for dose-intensified cancer therapy in the 1990s was the discovery that hematopoietic growth factors and peripheral blood progenitor cell infusions can ameliorate some of its associated hematologic toxicities. Both granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor accelerate neutrophil recovery after chemotherapy and can mobilize peripheral blood progenitor cells for use in autologous or allogeneic transplantation. Unfortunately, the duration and severity of chemotherapy-induced thrombocytopenia is unaffected by the use of these myeloid growth factors. During the last 5 years, the activities of a variety of potential platelet or megakaryocyte-stimulating factors have been determined in clinical trials. The results of these studies are described.

Original languageEnglish
Pages (from-to)253-260
Number of pages8
JournalSeminars in Hematology
Volume35
Issue number3
StatePublished - Jul 31 1998
Externally publishedYes

Fingerprint

Interleukin-11
Interleukin-3
Thrombocytopenia
Interleukin-6
Blood Cells
Intercellular Signaling Peptides and Proteins
Stem Cells
Drug Therapy
Megakaryocytes
Autologous Transplantation
Homologous Transplantation
Hematopoiesis
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor
Neoplasms
Neutrophils
Blood Platelets
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia. / Maslak, P.; Nimer, Stephen D.

In: Seminars in Hematology, Vol. 35, No. 3, 31.07.1998, p. 253-260.

Research output: Contribution to journalArticle

@article{b9bb669211e145f09c609717140f75b3,
title = "The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia",
abstract = "Suppression of normal hematopoiesis is a frequent complication of cancer or its treatment. The basis for dose-intensified cancer therapy in the 1990s was the discovery that hematopoietic growth factors and peripheral blood progenitor cell infusions can ameliorate some of its associated hematologic toxicities. Both granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor accelerate neutrophil recovery after chemotherapy and can mobilize peripheral blood progenitor cells for use in autologous or allogeneic transplantation. Unfortunately, the duration and severity of chemotherapy-induced thrombocytopenia is unaffected by the use of these myeloid growth factors. During the last 5 years, the activities of a variety of potential platelet or megakaryocyte-stimulating factors have been determined in clinical trials. The results of these studies are described.",
author = "P. Maslak and Nimer, {Stephen D}",
year = "1998",
month = "7",
day = "31",
language = "English",
volume = "35",
pages = "253--260",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - The efficacy of IL-3, SCF, IL-6, and IL-11 in treating thrombocytopenia

AU - Maslak, P.

AU - Nimer, Stephen D

PY - 1998/7/31

Y1 - 1998/7/31

N2 - Suppression of normal hematopoiesis is a frequent complication of cancer or its treatment. The basis for dose-intensified cancer therapy in the 1990s was the discovery that hematopoietic growth factors and peripheral blood progenitor cell infusions can ameliorate some of its associated hematologic toxicities. Both granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor accelerate neutrophil recovery after chemotherapy and can mobilize peripheral blood progenitor cells for use in autologous or allogeneic transplantation. Unfortunately, the duration and severity of chemotherapy-induced thrombocytopenia is unaffected by the use of these myeloid growth factors. During the last 5 years, the activities of a variety of potential platelet or megakaryocyte-stimulating factors have been determined in clinical trials. The results of these studies are described.

AB - Suppression of normal hematopoiesis is a frequent complication of cancer or its treatment. The basis for dose-intensified cancer therapy in the 1990s was the discovery that hematopoietic growth factors and peripheral blood progenitor cell infusions can ameliorate some of its associated hematologic toxicities. Both granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor accelerate neutrophil recovery after chemotherapy and can mobilize peripheral blood progenitor cells for use in autologous or allogeneic transplantation. Unfortunately, the duration and severity of chemotherapy-induced thrombocytopenia is unaffected by the use of these myeloid growth factors. During the last 5 years, the activities of a variety of potential platelet or megakaryocyte-stimulating factors have been determined in clinical trials. The results of these studies are described.

UR - http://www.scopus.com/inward/record.url?scp=0031815303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031815303&partnerID=8YFLogxK

M3 - Article

C2 - 9685171

AN - SCOPUS:0031815303

VL - 35

SP - 253

EP - 260

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 3

ER -